Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers.

Trial Profile

Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2011

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms ENCORE3
  • Most Recent Events

    • 17 Dec 2010 Status changed from recruiting to completed, results have been published.
    • 17 Dec 2010 Results have been published in the Journal of Antimicrobial Chemotherapy
    • 02 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top